Literature DB >> 24763002

[Expression and clinical significance of miR-21 in diffuse large B cell lymphoma].

Chun-Hong Li1, Rong Fu2, Yi-Hao Wang1, Wen-Jing Song1, Er-Bao Ruan1, Wen Qu1, Hua-Quan Wang1, Guo-Jin Wang1, Jia Song1, Xiao-Ming Wang1, Yu-Hong Wu1, Li-Min Xing1, Hong Liu1, Li-Juan Li1, Jing Guan1, Zong-Hong Shao3.   

Abstract

This study was aimed to investigate the expression of microRNA-21 and its correlation with PTEN in diffuse large B cell lymphoma (DLBCL) paraffin-embedded tissues, and evaluate its potential relevance with clinical characteristics. The expression levels of miR-21 in 26 primary DLBCL and 10 normal lymph node tissue specimens were examined by real-time polymerase chain reaction. The expression of PTEN was detected by immunohistochemical staining. The results indicated that the expression of miR-21 was significantly higher in tumor tissues [6.586(1.10,38.22)] than that in normal tissues [0.791 (0.35,2.87)] (P < 0.05). Among 26 patients with DLBCL the expression of PTEN protein was positive in 6 patients (23%), and was negative in 20 patients (77%). In patients with DLBCL, the expression level of miR-21 was negatively correlated with the level of PTEN protein. The high expression of miR-21 was positively correlated with the level of serum LDH. The expression level of miR-21 in patients with Ann Arbor III-IV stage was obviously higher than that of patients with Ann Arbor I-II stage, but did not correlate with the subtype of patients in clinic (P > 0.05). It is concluded that the expression of miR-21 is high in DLBCL and its overexpression may be related with poor prognosis of DLCBL. These findings suggest that PTEN is possibly one of the targets of miR-21 in DLBCL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24763002     DOI: 10.7534/j.issn.1009-2137.2014.02.014

Source DB:  PubMed          Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi        ISSN: 1009-2137


  1 in total

1.  MicroRNAs in diffuse large B-cell lymphoma.

Authors:  Huiyun Ni; Rong Tong; Linqing Zou; Guoqi Song; William C Cho
Journal:  Oncol Lett       Date:  2015-12-28       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.